RxSight (RXST) Corporate presentation summary

Vision and innovation

• Aims to transform cataract surgery outcomes through lens adjustability, validated by 30 years of innovation and over 300,000 implants.

• Adjustable lens technology delivers unmatched refractive precision, with LAL eyes showing 14.5 times better odds of optimal visual outcomes.

Clinical and patient outcomes

• Real-world data from over 3,000 eyes shows over 94% accuracy within +/- MRSE 1.

• More than 90% achieve 20/25 distance and J2 near vision without glasses.

• 90% of surveyed customers believe LAL provides the highest quality of vision; 79% would choose it for their own surgery.

Market adoption and economics

• 40% of LAL patients would have otherwise chosen a standard lens, expanding the premium market.

• Practices gain an average of $2,064 additional net revenue per LAL implanted.

• LAL units and installed base have grown significantly, with total revenue rising from $14.7M in 2020 to $139.9M projected for 2025.

• Q1 2026 revenue reached $30.9M, with 27,472 LALs sold and a 76.1% gross margin.